You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 60 Use of the Combined Positive Score (CPS) with the companion diagnostic PD-L1 IHC 22C3 pharmDx provides precise evaluation of PD-L1 expression across multiple tumor indications and cutoffs

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Biomarkers, Immune Monitoring, and Novel Technologies
60 Use of the Combined Positive Score (CPS) with the companion diagnostic PD-L1 IHC 22C3 pharmDx provides precise evaluation of PD-L1 expression across multiple tumor indications and cutoffs
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to September 2024

AbstractFullPdf
Nov 2021213014
Dec 20215608
Jan 2022154025
Feb 202264012
Mar 2022594013
Apr 2022226016
May 2022312021
Jun 2022608032
Jul 2022840043
Aug 2022878044
Sep 2022752033
Oct 2022772036
Nov 2022706041
Dec 2022600032
Jan 2023674025
Feb 2023606024
Mar 2023812036
Apr 2023634030
May 2023636024
Jun 2023572019
Jul 2023472023
Aug 2023582013
Sep 2023596024
Oct 2023532016
Nov 2023524019
Dec 2023394011
Jan 20245403
Feb 2024207010
Mar 202430602
Apr 202418605
May 202418207
Jun 2024218012
Jul 2024201014
Aug 2024114014
Sep 202410205
Total153790706